A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours
- First Posted Date
- 2025-03-13
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- LaNova Medicines Limited
- Target Recruit Count
- 84
- Registration Number
- NCT06873854
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours
- First Posted Date
- 2025-03-10
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- LaNova Medicines Limited
- Target Recruit Count
- 87
- Registration Number
- NCT06868199
- Locations
- 🇦🇺
Cancer Care Wollongong, Wollongong, New South Wales, Australia
🇦🇺Sunshine Coast University Private Hospital, Birtinya, Queensland, Australia
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: Toripalimab/Tirelizumab
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- LaNova Medicines Limited
- Target Recruit Count
- 320
- Registration Number
- NCT06682780
- Locations
- 🇨🇳
FuDan University Shanghai Cancer Center, Shanghai, Shanghai, China
Study of LM-299 in Subjects Advanced Malignant Tumors
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- LaNova Medicines Limited
- Target Recruit Count
- 108
- Registration Number
- NCT06650566
- Locations
- 🇦🇺
One Clinical Research, Perth, West Australia, Australia
🇨🇳the first affiliated hospital of Xinxiang medical University, Xinxiang, Henan, China
🇨🇳Liaocheng people's hospital, Liaocheng, Shandong, China
A Study of LM-24C5 For Advanced Solid Tumors
- First Posted Date
- 2024-01-02
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- LaNova Medicines Limited
- Target Recruit Count
- 49
- Registration Number
- NCT06187402
- Locations
- 🇺🇸
The Christ Hospital, Cincinnati, Ohio, United States
🇺🇸University of Southern California (USC) - Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Mary Crowley Cancer Research Center, Dallas, Texas, United States
Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases
- Conditions
- Relapsed or Refractory Multiple MyelomaOther Plasma Cell Diseases
- Interventions
- First Posted Date
- 2022-12-12
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- LaNova Medicines Limited
- Registration Number
- NCT05647512
A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- LaNova Medicines Limited
- Target Recruit Count
- 139
- Registration Number
- NCT05615974
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
🇨🇳Linyi Cancer Hospital, Linyi, Shandong, China
Study of LM-108 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- LaNova Medicines Limited
- Target Recruit Count
- 392
- Registration Number
- NCT05518045
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- LaNova Medicines Limited
- Target Recruit Count
- 24
- Registration Number
- NCT05255484
- Locations
- 🇺🇸
University of Oklahoma, Norman, Oklahoma, United States
🇺🇸Gabrail Cancer and Research Center, Canton, Ohio, United States
🇺🇸Ocala Oncology Center, Ocala, Florida, United States
A Clinical Study Preliminary Efficacy of LM-061 Tablet in Subjects With Advanced Tumours
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- LaNova Medicines Limited
- Target Recruit Count
- 18
- Registration Number
- NCT04882176
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai City, China